Overnight Market report, page-857

With standard of care in lung and breast cancer being chemo,and EFTI having comparable results , without the toxicity,where is the duty of care if fast track approval isn’t granted,you would imagine it’s just a matter of time now.For mine news on some kind of collaboration on lung cancer , with FDA fast track granted comes before the September lung cancer conference.Purely speculation on my behalf

It doesn’t make sense that BP wouldn’t want to collaborate in the worlds largest indication , with potentially fast track , and data as good as there currently is,,,am I missing something?